Browse by Title

Type here to filter the list

S
Sarcomatoid and Rhadoid De-Differentiation in Renal Cell Carcinoma and Clinical Implications
Favorite

Bradley C. Leibovich, MD (he/him/his) – Mayo Clinic ### 1678492###Speaker###Professor of Urology###Mayo Clinic###
Speaker: Bradley C. Leibovich, MD (he/him/his) – Mayo Clinic
### he/him/his
Session 1 Q&A
Favorite

Lars Lund, MD, PhD – University of Southern Denmark ### 1570694###Moderator###Professor, Head of research,###University of Southern Denmark###
Moderator: Lars Lund, MD, PhD – University of Southern Denmark
### @@@ Bradley C. Leibovich, MD (he/him/his) – Mayo Clinic ### 1678492###Moderator###Professor of Urology###Mayo Clinic###
Moderator: Bradley C. Leibovich, MD (he/him/his) – Mayo Clinic
### he/him/his
SESSION 10: BASIC SCIENCE INTEGRATED INTO THERAPEUTIC MANAGEMENT
Favorite

Annika Fendler, PhD – Charité - University Hospital ### 1828469###Moderator###Group Leader###Charité - University Hospital###
Moderator: Annika Fendler, PhD – Charité - University Hospital
### @@@ Elizabeth (Lisa) Henske, MD – Brigham and Women's Hospital, Harvard Medical School ### 1828452###Moderator###Physician, Principal Investigator###Brigham and Women's Hospital, Harvard Medical School###
Moderator: Elizabeth (Lisa) Henske, MD – Brigham and Women's Hospital, Harvard Medical School
###
Session 10 Q&A
Favorite

Annika Fendler, PhD – Charité - University Hospital ### 1828469###Moderator###Group Leader###Charité - University Hospital###
Moderator: Annika Fendler, PhD – Charité - University Hospital
### @@@ Elizabeth (Lisa) Henske, MD – Brigham and Women's Hospital, Harvard Medical School ### 1828452###Moderator###Physician, Principal Investigator###Brigham and Women's Hospital, Harvard Medical School###
Moderator: Elizabeth (Lisa) Henske, MD – Brigham and Women's Hospital, Harvard Medical School
###
Session 11 Q&A
Favorite

Sylvie Negrier, MD PhD (she/her/hers) – Centre Leon Bérard, Lyon I University ### 1828473###Moderator###Medical Oncologist###Centre Leon Bérard, Lyon I University###
Moderator: Sylvie Negrier, MD PhD (she/her/hers) – Centre Leon Bérard, Lyon I University
### she/her/hers @@@ Nizar M. Tannir, MD FACP (he/him/his) – University of Texas MD Anderson Cancer Center ### 1777863###Moderator###Professor###University of Texas MD Anderson Cancer Center###
Moderator: Nizar M. Tannir, MD FACP (he/him/his) – University of Texas MD Anderson Cancer Center
### he/him/his
SESSION 11: SPECIAL TOPICS
Favorite

Sylvie Negrier, MD PhD (she/her/hers) – Centre Leon Bérard, Lyon I University ### 1828473###Moderator###Medical Oncologist###Centre Leon Bérard, Lyon I University###
Moderator: Sylvie Negrier, MD PhD (she/her/hers) – Centre Leon Bérard, Lyon I University
### she/her/hers @@@ Nizar M. Tannir, MD FACP (he/him/his) – University of Texas MD Anderson Cancer Center ### 1777863###Moderator###Professor###University of Texas MD Anderson Cancer Center###
Moderator: Nizar M. Tannir, MD FACP (he/him/his) – University of Texas MD Anderson Cancer Center
### he/him/his
Session 2 Q&A
Favorite

Samra Turajlic, PhD, MBBS, MRCP (she/her/hers) – The Francis Crick Institute/ The Royal Marsden Hospital ### 1570697###Moderator###: Group Leader (Cancer Dynamics Laboratory, Francis Crick Institute) and Consultant Medical Oncologist (Royal Marsden NHS Foundation Trust)###The Francis Crick Institute/ The Royal Marsden Hospital###
Moderator: Samra Turajlic, PhD, MBBS, MRCP (she/her/hers) – The Francis Crick Institute/ The Royal Marsden Hospital
### she/her/hers @@@ Elizabeth (Lisa) Henske, MD – Brigham and Women's Hospital, Harvard Medical School ### 1828452###Moderator###Physician, Principal Investigator###Brigham and Women's Hospital, Harvard Medical School###
Moderator: Elizabeth (Lisa) Henske, MD – Brigham and Women's Hospital, Harvard Medical School
###
SESSION 2: Understanding Renal Cell Carcinoma
Favorite

Samra Turajlic, PhD, MBBS, MRCP (she/her/hers) – The Francis Crick Institute/ The Royal Marsden Hospital ### 1570697###Moderator###: Group Leader (Cancer Dynamics Laboratory, Francis Crick Institute) and Consultant Medical Oncologist (Royal Marsden NHS Foundation Trust)###The Francis Crick Institute/ The Royal Marsden Hospital###
Moderator: Samra Turajlic, PhD, MBBS, MRCP (she/her/hers) – The Francis Crick Institute/ The Royal Marsden Hospital
### she/her/hers @@@ Elizabeth (Lisa) Henske, MD – Brigham and Women's Hospital, Harvard Medical School ### 1828452###Moderator###Physician, Principal Investigator###Brigham and Women's Hospital, Harvard Medical School###
Moderator: Elizabeth (Lisa) Henske, MD – Brigham and Women's Hospital, Harvard Medical School
###
SESSION 3: CARING FOR THE WHOLE PATIENT: NON CLINICAL CONSIDERATIONS
Favorite

Michael D. Staehler, MD, PhD – Ludwig-Maximilians University of Munich ### 1570696###Moderator###Head Multidisciplinary Center of Renal Tumors###Ludwig-Maximilians University of Munich###
Moderator: Michael D. Staehler, MD, PhD – Ludwig-Maximilians University of Munich
### @@@ Cristina Suárez Rodríguez, Sr., MD, PhD (she/her/hers) – Vall d'Hebron University Hospital ### 1570705###Moderator###Attending Physician###Vall d'Hebron University Hospital###
Moderator: Cristina Suárez Rodríguez, Sr., MD, PhD (she/her/hers) – Vall d'Hebron University Hospital
### she/her/hers
Session 3: Panel discussion & Q&A
Favorite

Michael D. Staehler, MD, PhD – Ludwig-Maximilians University of Munich ### 1570696###Moderator###Head Multidisciplinary Center of Renal Tumors###Ludwig-Maximilians University of Munich###
Moderator: Michael D. Staehler, MD, PhD – Ludwig-Maximilians University of Munich
### @@@ Cristina Suárez Rodríguez, Sr., MD, PhD (she/her/hers) – Vall d'Hebron University Hospital ### 1570705###Moderator###Attending Physician###Vall d'Hebron University Hospital###
Moderator: Cristina Suárez Rodríguez, Sr., MD, PhD (she/her/hers) – Vall d'Hebron University Hospital
### she/her/hers
SESSION 4: ORAL ABSTRACTS
Favorite

Gabriel Malouf, MD, PhD – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University ### 1570718###Moderator######Institut de Cancérologie de Strasbourg-Europe, Strasbourg University###
Moderator: Gabriel Malouf, MD, PhD – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University
### @@@ Lars Lund, MD, PhD – University of Southern Denmark ### 1570694###Moderator###Professor, Head of research,###University of Southern Denmark###
Moderator: Lars Lund, MD, PhD – University of Southern Denmark
###
Session 4 Q&A
Favorite

Gabriel Malouf, MD, PhD – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University ### 1570718###Moderator######Institut de Cancérologie de Strasbourg-Europe, Strasbourg University###
Moderator: Gabriel Malouf, MD, PhD – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University
### @@@ Lars Lund, MD, PhD – University of Southern Denmark ### 1570694###Moderator###Professor, Head of research,###University of Southern Denmark###
Moderator: Lars Lund, MD, PhD – University of Southern Denmark
###
SESSION 5: FIRST-LINE THERAPY DEBATES
Favorite

Viktor Gruenwald, MD PhD (he/him/his) – Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany ### 1570693###Moderator###Professor for interdisciplinary GU Oncology###Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany###
Moderator: Viktor Gruenwald, MD PhD (he/him/his) – Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany
### he/him/his @@@ Lisa Pickering, MD, PhD (she/her/hers) – The Royal Marsden NHS Foundation Trust ### 1570703###Moderator###Consultant Medical Oncologist###The Royal Marsden NHS Foundation Trust###
Moderator: Lisa Pickering, MD, PhD (she/her/hers) – The Royal Marsden NHS Foundation Trust
### she/her/hers
Session 5: Panel discussion and Q&A
Favorite

Viktor Gruenwald, MD PhD (he/him/his) – Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany ### 1570693###Moderator###Professor for interdisciplinary GU Oncology###Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany###
Moderator: Viktor Gruenwald, MD PhD (he/him/his) – Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany
### he/him/his @@@ Lisa Pickering, MD, PhD (she/her/hers) – The Royal Marsden NHS Foundation Trust ### 1570703###Moderator###Consultant Medical Oncologist###The Royal Marsden NHS Foundation Trust###
Moderator: Lisa Pickering, MD, PhD (she/her/hers) – The Royal Marsden NHS Foundation Trust
### she/her/hers
SESSION 7: BEYOND FIRST-LINE THERAPY
Favorite

Laurence Albiges, MD, PhD (she/her/hers) – Institut Gustave Roussy ### 1570687###Moderator###Professor and Chairman, Medical Oncology Department, Gustave Roussy Cancer Center, Villejuif, France###Institut Gustave Roussy###
Moderator: Laurence Albiges, MD, PhD (she/her/hers) – Institut Gustave Roussy
### she/her/hers @@@ Daniel J. George, MD (he/him/his) – Duke University Medical Center ### 1570692###Moderator###Professor of Medicine and Surgery###Duke University Medical Center###
Moderator: Daniel J. George, MD (he/him/his) – Duke University Medical Center
### he/him/his
SESSION 8 - MANAGEMENT OF RCC
Favorite

Sylvie Negrier, MD PhD (she/her/hers) – Centre Leon Bérard, Lyon I University ### 1828473###Moderator###Medical Oncologist###Centre Leon Bérard, Lyon I University###
Moderator: Sylvie Negrier, MD PhD (she/her/hers) – Centre Leon Bérard, Lyon I University
### she/her/hers @@@ Ulka N. Vaishampayan, MD (she/her/hers) – University of Michigan ### 1828463###Moderator###Professor of Medicine/Oncology###University of Michigan###
Moderator: Ulka N. Vaishampayan, MD (she/her/hers) – University of Michigan
### she/her/hers
SESSION 9: PROGRESS IN THE TREATMENT OF VARIANT HISTOLOGY RCC
Favorite

Cristina Suárez Rodríguez, Sr., MD, PhD (she/her/hers) – Vall d'Hebron University Hospital ### 1570705###Moderator###Attending Physician###Vall d'Hebron University Hospital###
Moderator: Cristina Suárez Rodríguez, Sr., MD, PhD (she/her/hers) – Vall d'Hebron University Hospital
### she/her/hers @@@ Michael B. Atkins, MD (he/him/his) – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA. ### 1777872###Moderator###Vice Chair of Department of Medical Oncology###Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.###
Moderator: Michael B. Atkins, MD (he/him/his) – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
### he/him/his
SESSION CLOSING
Favorite

Michael D. Staehler, MD, PhD – Ludwig-Maximilians University of Munich ### 1570696###Moderator###Head Multidisciplinary Center of Renal Tumors###Ludwig-Maximilians University of Munich###
Moderator: Michael D. Staehler, MD, PhD – Ludwig-Maximilians University of Munich
### @@@ Gabriel Malouf, MD, PhD – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University ### 1570718###Moderator######Institut de Cancérologie de Strasbourg-Europe, Strasbourg University###
Moderator: Gabriel Malouf, MD, PhD – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University
###
Supplements and Concomitant Drugs - Interactions, Efficacy
Favorite

Dora Niedersüß-Beke, MD, MBA – Klinik Ottakring ### 1828455###Speaker###Senior doctor###Klinik Ottakring###
Speaker: Dora Niedersüß-Beke, MD, MBA – Klinik Ottakring
###